ExpressionEdits emerges with $13m to transform genetic medicine

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Company’s AI-powered ‘intronization’ technology enhances protein expression and may help unlock new therapeutics for age-related diseases.

British biotech startup ExpressionEdits has raised $13 million in a seed funding round to support its mission to aims to revolutionize genetic medicine. Founded in 2021 by Dr Kärt Tomberg, Professor Allan Bradley and Dr Liliana Antunes, the Cambridge-based company leverages an AI-powered platform that integrates millions of biological data points with machine learning algorithms to automate the optimization of gene design.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE